Why aren’t more technologies with promise moving beyond basic research?

3 PRINCIPAL REASONS:

- Scarcity of funding between laboratory bench and clinical proof of concept, particularly in current economic climate.
- Risk perceived as too high, and, consequently, short and mid term, ROI too low, to attract private equity, in spite of long range potential for improving cardiovascular health.
- Scientists often lack the clinical development experience to gain regulatory approval as well as the business skills necessary to commercialize their innovations.

Overcoming the ‘Valley of Death’

- Research grants can only take scientific advances so far.
- Many investors are unwilling to accept early stage development risks.
- The funding void between promising innovations and the market is commonly referred to as the “Valley of Death.”
- The Science & Technology Accelerator was established to help propel revolutionary innovations across the “Valley of Death.”

Accelerator INVESTMENT Focus

<table>
<thead>
<tr>
<th>Basic research and validation</th>
<th>Pre-clinical</th>
<th>First in human</th>
<th>Proof of Concept</th>
<th>Pivotal Trials</th>
<th>Registration and Commercialization</th>
</tr>
</thead>
<tbody>
<tr>
<td>↩Funding available from</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NIH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AHA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Foundations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

“Valley of Death”
The Accelerator program fills the void by:

- Identifying revolutionary technologies
  - aligned with AHA’s mission and its 2020 Goals to reduce death from heart attack and stroke by 20% by 2020
  - with the potential to become “game changers,” but
  - too early in development to gain traction with private equity or industry
- Bringing their innovators together with
  - investment capital
  - AHA’s cadre of expert clinical development, regulatory affairs, intellectual property, and commercialization experts committed to success of Accelerator investments

... with the aim of accelerating movement of these technologies from the bench to bedside quickly

Summary and Next Steps

- AHA’s Science & Technology Accelerator is accelerating the pace at which life-saving technologies are brought to the public
- We seek to create A FUTURE WHERE NO GAME CHANGING, RESEARCH Languishes IN THE LAB DUE TO LACK OF FINANCIAL SUPPORT
- AHA leadership is deeply committed to this new initiative
- The Science & Technology Accelerator depends SOLELY on direct donor funding
- Any return on Investment will be reinvested in additional transformational innovations
- WE DEPEND ENTIRELY ON DIRECT DONATIONS TO THE PROGRAM